
As Genmab gets bigger on all parameters, so too increases the attention from lawyers and legal departments from competitors across the globe, says CEO of Genmab Jan van de Winkel, as reported by Danish business daily Børsen.
”Each case is different, but the reality is that as you become more successful you also find yourself legally challenged more often. I think we need to expect this will happen again in the future,” van de Winkel says.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app